Chemical: Drug
benazepril

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.



PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for benazepril

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA VA
rs1042713 NC_000005.10:g.148826877G=, NC_000005.10:g.148826877G>A, NC_000005.9:g.148206440G=, NC_000005.9:g.148206440G>A, NG_016421.1:g.5285A=, NG_016421.1:g.5285A>G, NM_000024.5:c.46A=, NM_000024.5:c.46A>G, NP_000015.1:p.Arg16=, NP_000015.1:p.Arg16Gly, XM_005268382.1:c.46G=, XM_005268382.1:c.46G>A, XM_005268383.1:c.46G=, XM_005268383.1:c.46G>A, XP_005268439.1:p.Gly16=, XP_005268439.1:p.Gly16Arg, XP_005268440.1:p.Gly16=, XP_005268440.1:p.Gly16Arg, rs17287432, rs17334179, rs17334242, rs17721693, rs17839749, rs17846639, rs17859732, rs3182174, rs3729940, rs52812686, rs56964295
G > A
SNP
R16G
No VIP available CA VA
rs1799752 NC_000017.10:g.61565890_61565891insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, NC_000017.10:g.61565890_61565891insG, NC_000017.11:g.63488529_63488530insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, NC_000017.11:g.63488529_63488530insG, NG_011648.1:g.16457_16458insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, NG_011648.1:g.16457_16458insG, NM_000789.3:c.2306-119_2306-118insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, NM_000789.3:c.2306-119_2306-118insG, NM_001178057.1:c.584-119_584-118insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, NM_001178057.1:c.584-119_584-118insG, NM_152830.2:c.584-119_584-118insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, NM_152830.2:c.584-119_584-118insG, XM_005257110.1:c.1757-119_1757-118insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, XM_005257110.1:c.1757-119_1757-118insG, XM_006721737.2:c.644-119_644-118insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, XM_006721737.2:c.644-119_644-118insG
- > ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC
- > G
indel
No VIP available CA VA
rs1799998 NC_000008.10:g.143999600A=, NC_000008.10:g.143999600A>G, NC_000008.11:g.142918184A=, NC_000008.11:g.142918184A>G, NG_008374.1:g.4660T=, NG_008374.1:g.4660T>C, NM_000498.3:c.-344T=, NM_000498.3:c.-344T>C, XM_011516877.1:c.-344T=, XM_011516877.1:c.-344T>C, XM_011516878.1:c.-344T=, XM_011516878.1:c.-344T>C, XM_011516879.1:c.-344T=, XM_011516879.1:c.-344T>C, XR_928729.1:n.-1946A=, XR_928729.1:n.-1946A>G, rs17777877, rs60977059
A > G
SNP
No VIP available No Clinical Annotations available VA
rs1801131 NC_000001.10:g.11854476T>G, NC_000001.11:g.11794419T>G, NG_013351.1:g.16685A>C, NM_005957.4:c.1286A>C, NP_005948.3:p.Glu429Ala, XM_005263458.1:c.1409A>C, XM_005263458.2:c.1409A>C, XM_005263459.1:c.1355A>C, XM_005263460.1:c.1286A>C, XM_005263460.3:c.1286A>C, XM_005263461.1:c.1286A>C, XM_005263461.3:c.1286A>C, XM_005263462.1:c.1286A>C, XM_005263462.3:c.1286A>C, XM_005263463.1:c.1040A>C, XM_005263463.2:c.1040A>C, XM_011541495.1:c.1406A>C, XM_011541496.1:c.1409A>C, XP_005263515.1:p.Glu470Ala, XP_005263516.1:p.Glu452Ala, XP_005263517.1:p.Glu429Ala, XP_005263518.1:p.Glu429Ala, XP_005263519.1:p.Glu429Ala, XP_005263520.1:p.Glu347Ala, XP_011539797.1:p.Glu469Ala, XP_011539798.1:p.Glu470Ala, rs17367365, rs17857426, rs4134712
T > G
SNP
E429A
No VIP available CA VA
rs1801133 NC_000001.10:g.11856378G>A, NC_000001.11:g.11796321G>A, NG_013351.1:g.14783C>T, NM_005957.4:c.665C>T, NP_005948.3:p.Ala222Val, XM_005263458.1:c.788C>T, XM_005263458.2:c.788C>T, XM_005263459.1:c.734C>T, XM_005263460.1:c.665C>T, XM_005263460.3:c.665C>T, XM_005263461.1:c.665C>T, XM_005263461.3:c.665C>T, XM_005263462.1:c.665C>T, XM_005263462.3:c.665C>T, XM_005263463.1:c.419C>T, XM_005263463.2:c.419C>T, XM_011541495.1:c.785C>T, XM_011541496.1:c.788C>T, XP_005263515.1:p.Ala263Val, XP_005263516.1:p.Ala245Val, XP_005263517.1:p.Ala222Val, XP_005263518.1:p.Ala222Val, XP_005263519.1:p.Ala222Val, XP_005263520.1:p.Ala140Val, XP_011539797.1:p.Ala262Val, XP_011539798.1:p.Ala263Val, rs386545618, rs4134713, rs59514310
G > A
SNP
A222V
No VIP available CA VA
rs1805087 NC_000001.10:g.237048500A>G, NC_000001.11:g.236885200A>G, NG_008959.1:g.94920A>G, NM_000254.2:c.2756A>G, NM_001291939.1:c.2603A>G, NM_001291940.1:c.1535A>G, NP_000245.2:p.Asp919Gly, NP_001278868.1:p.Asp868Gly, NP_001278869.1:p.Asp512Gly, XM_005273140.1:c.2924A>G, XM_005273141.1:c.2753A>G, XM_005273141.3:c.2753A>G, XM_005273142.1:c.2666A>G, XM_005273143.1:c.2603A>G, XM_005273144.1:c.2318A>G, XM_005273145.1:c.1118A>G, XM_006711769.2:c.2756A>G, XM_006711770.1:c.1820A>G, XM_011544193.1:c.2567A>G, XM_011544194.1:c.2924A>G, XP_005273197.1:p.Asp975Gly, XP_005273198.1:p.Asp918Gly, XP_005273199.1:p.Asp889Gly, XP_005273200.1:p.Asp868Gly, XP_005273201.1:p.Asp773Gly, XP_005273202.1:p.Asp373Gly, XP_006711832.1:p.Asp919Gly, XP_006711833.1:p.Asp607Gly, XP_011542495.1:p.Asp856Gly, XP_011542496.1:p.Asp975Gly, rs17658739, rs56618494, rs61036243
A > G
SNP
D919G
No VIP available No Clinical Annotations available VA
rs2106089 NC_000001.10:g.158628627A>G, NC_000001.11:g.158658837A>G, NG_011474.1:g.32880T>C, NM_003126.2:c.2588-1143T>C, XM_011509916.1:c.2588-1143T>C, XM_011509917.1:c.2588-1143T>C, XM_011509918.1:c.2588-1143T>C, XM_011509919.1:c.2588-1143T>C, XR_921911.1:n.2701-1143T>C, XR_921912.1:n.2706-1143T>C, rs3944272, rs3945341, rs4576658
A > G
SNP
No VIP available CA VA
rs2229437 NC_000011.10:g.82853252T>G, NC_000011.9:g.82564294T>G, NM_001319214.1:c.21A>C, NM_005040.3:c.336A>C, NM_199418.3:c.399A>C, NP_001306143.1:p.Glu7Asp, NP_005031.1:p.Glu112Asp, NP_955450.2:p.Glu133Asp, XM_005274093.1:c.21A>C, XP_005274150.1:p.Glu7Asp, rs117542437, rs17649579, rs2298668, rs386564200, rs52813874
T > G
SNP
E7D
No VIP available No Clinical Annotations available VA
rs2640543 NC_000003.11:g.148432369A>G, NC_000003.12:g.148714582A>G, NG_008468.1:g.21712A>G, NM_000685.4:c.-48+6555A>G, NM_004835.4:c.1-15598A>G, NM_009585.3:c.-48+16455A>G, NM_031850.3:c.-1+6555A>G, rs17237176, rs59156576
A > G
SNP
No VIP available No Clinical Annotations available VA
rs4762 NC_000001.10:g.230845977G>A, NC_000001.11:g.230710231G>A, NG_008836.1:g.9360C>T, NM_000029.3:c.620C>T, NP_000020.1:p.Thr207Met, rs16852387, rs3182294, rs52830531, rs60395225
G > A
SNP
T207M
No VIP available No Clinical Annotations available VA
rs4961 NC_000004.11:g.2906707G>T, NC_000004.12:g.2904980G>T, NG_012037.1:g.66124G>T, NM_001119.4:c.1378G>T, NM_001286645.1:c.1378G>T, NM_014189.3:c.1378G>T, NM_014190.3:c.1378G>T, NM_176801.2:c.1378G>T, NP_001110.2:p.Gly460Trp, NP_001273574.1:p.Gly460Trp, NP_054908.2:p.Gly460Trp, NP_054909.2:p.Gly460Trp, NP_789771.1:p.Gly460Trp, XM_005247933.1:c.1378G>T, XM_005247934.1:c.1378G>T, XM_005247935.1:c.1378G>T, XM_005247936.1:c.1378G>T, XM_005247937.1:c.1378G>T, XM_005247938.1:c.1378G>T, XP_005247990.1:p.Gly460Trp, XP_005247991.1:p.Gly460Trp, XP_005247992.1:p.Gly460Trp, XP_005247993.1:p.Gly460Trp, XP_005247994.1:p.Gly460Trp, XP_005247995.1:p.Gly460Trp, rs113752720, rs52823896, rs61347248
G > T
SNP
G460W
No VIP available CA VA
rs5051 NC_000001.10:g.230849872C>T, NC_000001.11:g.230714126C>T, NG_008836.1:g.5465G>A, NM_000029.3:c.-44G>A, rs16852405, rs36218427, rs3789681, rs60366145
C > T
SNP
No VIP available No Clinical Annotations available VA
rs699 NC_000001.10:g.230845794A>G, NC_000001.11:g.230710048A>G, NG_008836.1:g.9543T>C, NM_000029.3:c.803T>C, NP_000020.1:p.Met268Thr, rs17856353, rs3182295, rs386606420, rs4714, rs61617185
A > G
SNP
M268T
No VIP available CA VA
rs7079 NC_000001.10:g.230838331G>T, NC_000001.11:g.230702585G>T, NG_008836.1:g.17006C>A, NM_000029.3:c.*556C>A, rs17729100, rs3182672, rs59584810
G > T
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Generic Names
  • benazepril
Trade Names
  • Benazepril HCl
  • Benazepril Hydrochloride
  • Benazeprilum [Latin]
  • Briem
  • Cibacen
  • Cibacene
  • Lotensin
Brand Mixture Names
  • Lotensin HCT (Benazepril Hydrochloride + Hydrochlorothiazide)
  • Lotrel (Benazepril Hydrochloride + Amlodipine Besylate)

PharmGKB Accession Id

PA448561

Type(s):

Drug

Description

Benazepril, brand name Lotensin, is a medication used to treat high blood pressure (hypertension), congestive heart failure, and chronic renal failure. Upon cleavage of its ester group by the liver, benazepril is converted into its active form benazeprilat, a non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor.

Source: Drug Bank

Indication

For the treatment of hypertension. It may be used alone or in combination with thiazide diuretics.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Benazeprilat, the active metabolite of Benazepril, competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. Inhibition of ACE results in decreased plasma angiotensin II. As angiotensin II is a vasoconstrictor and a negative-feedback mediator for renin activity, lower concentrations result in a decrease in blood pressure and stimulation of baroreceptor reflex mechanisms, which leads to decreased vasopressor activity and to decreased aldosterone secretion. Benazeprilat may also act on kininase II, an enzyme identical to ACE that degrades the vasodilator bradykinin.

Source: Drug Bank

Pharmacology

Benazepril, an angiotensin-converting enzyme (ACE) inhibitor, is a prodrug which, when hydrolyzed by estarases to its active Benazeprilat, is used to treat hypertension and heart failure, to reduce proteinuria and renal disease in patients with nephropathies, and to prevent stroke, myocardial infarction, and cardiac death in high-risk patients. Benazepril and Benazeprilat inhibit angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex.

Source: Drug Bank

Food Interaction

Benazepril may decrease the excretion of potassium. Salt um may increase the risk of hyperkalemia. substitutes containing potassi|Food slows absorption without decreasing the quantity absorbed.|High salt intake may attenuate the antihypertensive effect of benazepril.|Take without regard to meals.|Herbs that may attenuate the antihypertensive effect of benazepril include: bayberry, blue cohash, cayenne, ephedra, ginger, ginseng (American), kola and licorice.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Cleavage of the ester group (primarily in the liver) converts benazepril to its active metabolite, benazeprilat. Benazepril and benazeprilat may be conjugated to glucuronic acid prior to urinary excretion.

Source: Drug Bank

Protein Binding

benazepril, 97%; benazeprilat, 95%

Source: Drug Bank

Absorption

Peak in plasma within 0.5-1.0 hours. The extent of absorption is at least 37% as determined by urinary recovery and is not significantly influenced by the presence of food in the GI tract.

Source: Drug Bank

Half-Life

10-11 hours

Source: Drug Bank

Toxicity

Most likely symptom of overdosage is severe hypotension. Most common adverse effects include headache, dizziness, fatigue, somnolence, postural dizziness, nausea, and cough.

Source: Drug Bank

Route of Elimination

Benazepril and benazeprilat are cleared predominantly by renal excretion in healthy subjects with normal renal function. Nonrenal (i.e., biliary) excretion accounts for approximately 11%-12% of benazeprilat excretion in healthy subjects.

Source: Drug Bank

Chemical Properties

Chemical Formula

C24H28N2O5

Source: Drug Bank

Isomeric SMILES

CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCC3=CC=CC=C3N(C2=O)CC(=O)O

Source: Drug Bank

CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]1CCC2=C(C=CC=C2)N(CC(O)=O)C1=O

Source: Drug Bank

Canonical SMILES

CCOC(=O)[C@H]

Source: Drug Bank

Average Molecular Weight

424.4895

Source: Drug Bank

Monoisotopic Molecular Weight

424.199822016

Source: Drug Bank

SMILES

CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]1CCC2=CC=CC=C2N(CC(O)=O)C1=O

Source: Drug Bank

InChI String

InChI=1S/C24H28N2O5/c1-2-31-24(30)20(14-12-17-8-4-3-5-9-17)25-19-15-13-18-10-6-7-11-21(18)26(23(19)29)16-22(27)28/h3-11,19-20,25H,2,12-16H2,1H3,(H,27,28)/t19-,20-/m0/s1

Source: Drug Bank

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Drug Targets

Gene Description
ACE (source: Drug Bank)

Drug Interactions

Interaction Description
amiloride - benazepril Increased risk of hyperkaliemia (source: Drug Bank)
amiloride - benazepril Increased risk of hyperkaliemia (source: Drug Bank)
benazepril - amiloride Increased risk of hyperkaliemia (source: Drug Bank)
benazepril - amiloride Increased risk of hyperkaliemia (source: Drug Bank)
benazepril - drospirenone Increased risk of hyperkaliemia (source: Drug Bank)
benazepril - lithium The ACE inhibitor increases serum levels of lithium (source: Drug Bank)
benazepril - lithium The ACE inhibitor increases serum levels of lithium (source: Drug Bank)
benazepril - potassium Increased risk of hyperkaliemia (source: Drug Bank)
benazepril - potassium Increased risk of hyperkaliemia (source: Drug Bank)
benazepril - spironolactone Increased risk of hyperkaliemia (source: Drug Bank)
benazepril - spironolactone Increased risk of hyperkaliemia (source: Drug Bank)
benazepril - tizanidine Tizanidine increases the risk of hypotension with the ACE inhibitor (source: Drug Bank)
benazepril - tizanidine Tizanidine increases the risk of hypotension with the ACE inhibitor (source: Drug Bank)
benazepril - triamterene Increased risk of hyperkaliemia (source: Drug Bank)
benazepril - triamterene Increased risk of hyperkaliemia (source: Drug Bank)
lithium - benazepril The ACE inhibitor increases serum levels of lithium (source: Drug Bank)
lithium - benazepril The ACE inhibitor increases serum levels of lithium (source: Drug Bank)
tizanidine - benazepril Tizanidine increases the risk of hypotension with the ACE inhibitor (source: Drug Bank)
tizanidine - benazepril Tizanidine increases the risk of hypotension with the ACE inhibitor (source: Drug Bank)
treprostinil - benazepril Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. (source: Drug Bank)
triamterene - benazepril Increased risk of hyperkaliemia (source: Drug Bank)
triamterene - benazepril Increased risk of hyperkaliemia (source: Drug Bank)

Curated Information ?

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
May Prevent
Contraindicated With

Publications related to benazepril: 12

No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A core promoter variant of angiotensinogen gene and interindividual variation in response to angiotensin-converting enzyme inhibitors. Journal of the renin-angiotensin-aldosterone system : JRAAS. 2014. Yu Huimin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Interactions of renin-angiotensin system gene polymorphisms and antihypertensive effect of benazepril in Chinese population. Pharmacogenomics. 2011. Chen Qing, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
E112D polymorphism in the prolylcarboxypeptidase gene is associated with blood pressure response to benazepril in Chinese hypertensive patients. Chinese medical journal. 2009. Zhang Yan, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association between angiotensinogen, angiotensin II receptor genes, and blood pressure response to an angiotensin-converting enzyme inhibitor. Circulation. 2007. Su Xiaowen, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Associations between CYP11B2 gene polymorphisms and the response to angiotensin-converting enzyme inhibitors. Clinical pharmacology and therapeutics. 2006. Yu Hui-Min, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A common haplotype on methylenetetrahydrofolate reductase gene modifies the effect of angiotensin-converting enzyme inhibitor on blood pressure in essential hypertension patients--a family-based association study. Clinical and experimental hypertension (New York, N.Y. : 1993). 2005. Jiang Shanqun, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Associations of baseline blood pressure levels and efficacy of Benazepril treatment with interaction of alpha-adducin and ACE gene polymorphisms in hypertensives. Clinical and experimental hypertension (New York, N.Y. : 1993). 2005. Yu Yunxian, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A study of the relationships between angiotensin- converting enzyme gene, chymase gene polymorphisms, pharmacological treatment with ACE inhibitor and regression of left ventricular hypertrophy in essential hypertension patients treated with benazepril. Annals of human biology. 2005. He Hong, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Beta2 adrenergic receptor gene Arg16Gly polymorphism is associated with therapeutic efficacy of benazepril on essential hypertension in Chinese. Clinical and experimental hypertension (New York, N.Y. : 1993). 2004. Huang Guo, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
D919G polymorphism of methionine synthase gene is associated with blood pressure response to benazepril in Chinese hypertensive patients. Journal of human genetics. 2004. Zhang Yan, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The C677T polymorphism of the methylenetetrahydrofolate reductase gene is associated with the level of decrease on diastolic blood pressure in essential hypertension patients treated by angiotensin-converting enzyme inhibitor. Thrombosis research. 2004. Jiang Shanqun, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
ACE DD genotype is more susceptible than ACE II and ID genotypes to the antiproteinuric effect of ACE inhibitors in patients with proteinuric non-insulin-dependent diabetes mellitus. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2000. Ha S K, et al. PubMed

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
65162-751-03
DrugBank:
DB00542
ChEBI:
3011
KEGG Compound:
C06843
PubChem Compound:
5362124
PubChem Substance:
205187
46507884
Drugs Product Database (DPD):
885835
ChemSpider:
4514935
Therapeutic Targets Database:
DAP000584
FDA Drug Label at DailyMed:
a216253b-27cb-42ef-b5a8-67fb05aafb88

Clinical Trials

These are trials that mention benazepril and are related to either pharmacogenetics or pharmacogenomics.

No trials loaded.

NURSA Datasets

provided by nursa.org

No NURSA datasets available.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.